BackCK Life Sciences International (Holdings) Overview

CK Life Sciences International (Holdings) Current Assets

CK Life Sciences International (Holdings)'s current assets is $3.1B.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$3.10B
↓ 1.45% YoYΔ $-45.61M vs prior year quarter

Peer trimmed avg / median

Loading

CK Life Sciences International (Holdings) Current Assets History

Loading

CK Life Sciences International (Holdings) vs. peers: Current Assets Comparison

Loading

CK Life Sciences International (Holdings) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CK Life Sciences International (Holdings) (0775.HK) FAQ

CK Life Sciences International (Holdings)'s current assets stands at $3.1B as of June 2026. That compares with $3.1B in the prior-year period — down 1.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CK Life Sciences International (Holdings) reported $3.1B in current assets versus $3.1B a year earlier — a 1.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $3.1B in the prior-year period — down 1.4% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CK Life Sciences International (Holdings)'s current assets evolved across reporting periods, while the comparison chart places 0775.HK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. CK Life Sciences International (Holdings)'s reading of $3.1B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.